Hybio Pharmaceutical Balance Sheet

Financials in millions CNY. Fiscal year is January - December.

Millions CNY. Fiscal year is Jan - Dec.

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Mar '26 Mar 31, 2026	Dec '25 Dec 31, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Jan '23 Jan 1, 2023	Jan '22 Jan 1, 2022
Cash & Equivalents	107.58	100.72	94.87	344.01	106.26	138.92
Trading Asset Securities	1.16	1.23	1.11	-	160.57	477.68
Cash & Short-Term Investments	108.74	101.95	95.97	344.01	266.83	616.6
Cash Growth	82.62%	6.23%	-72.10%	28.92%	-56.73%	36.52%
Accounts Receivable	173.82	131.43	99.87	145.42	318.07	282.64
Other Receivables	6.88	6.55	11.15	22.44	11.88	54.39
Receivables	180.71	137.98	111.02	167.87	329.95	337.03
Inventory	337.41	261.38	238.63	152.59	189.96	157.14
Prepaid Expenses	-	-	10.29	2.56	0.19	-
Other Current Assets	32.45	22.24	7.14	16.61	25.39	44.31
Total Current Assets	659.31	523.56	463.05	683.64	812.32	1,155
Property, Plant & Equipment	1,767	1,745	1,674	1,734	1,942	1,993
Long-Term Investments	5.93	5.95	89.11	105.85	131.11	139.74
Goodwill	-	-	-	-	-	0.19
Other Intangible Assets	336.82	262.85	293.41	222.5	265.05	263.56
Long-Term Deferred Tax Assets	41.33	41.88	43.76	39.55	38.01	34.07
Long-Term Deferred Charges	125.45	200.7	175.99	217.81	250.41	228.02
Other Long-Term Assets	431.91	373.9	268.53	273.73	172.5	93.2
Total Assets	3,368	3,154	3,008	3,277	3,611	3,906
Accounts Payable	270.27	261.97	218.26	108.5	129.05	90.73
Accrued Expenses	14.13	28.64	78.5	100.92	49.16	72.78
Short-Term Debt	846.86	1,033	638.99	634.21	320.92	338.23
Current Portion of Long-Term Debt	153.11	249.98	293.53	453.18	456.11	63.05
Current Portion of Leases	-	-	0.82	0.21	2.88	11.06
Current Income Taxes Payable	13.32	16.02	6.72	2.84	-	0.32
Current Unearned Revenue	143.19	102.96	130.55	55.33	62.69	48.79
Other Current Liabilities	97.06	88.83	57.17	68.26	127.14	118.86
Total Current Liabilities	1,538	1,782	1,425	1,423	1,148	743.82
Long-Term Debt	955.6	623.4	864.58	942.05	1,026	1,377
Long-Term Unearned Revenue	94.73	97.69	106.91	101.19	118.62	124.73
Long-Term Deferred Tax Liabilities	16.02	15.41	8.84	5.01	4.2	0.81
Other Long-Term Liabilities	5.82	5.82	6.29	22.29	17.06	12.3
Total Liabilities	2,610	2,524	2,411	2,494	2,314	2,258
Common Stock	883.24	883.24	883.24	883.24	916.93	916.93
Additional Paid-In Capital	1,448	1,448	1,448	1,463	1,748	1,700
Retained Earnings	-1,629	-1,757	-1,794	-1,627	-1,113	-740
Treasury Stock	-	-	-	-	-318.66	-318.66
Comprehensive Income & Other	39.7	39.97	41.22	39.27	37.5	26.51
Total Common Equity	741.56	613.95	578.63	758.8	1,271	1,585
Minority Interest	15.56	15.98	18.42	24.41	26.3	63.31
Shareholders' Equity	757.11	629.93	597.05	783.21	1,297	1,648
Total Liabilities & Equity	3,368	3,154	3,008	3,277	3,611	3,906
Total Debt	1,956	1,907	1,798	2,030	1,806	1,789
Net Cash (Debt)	-1,847	-1,805	-1,702	-1,686	-1,540	-1,173
Net Cash Per Share	-2.00	-1.97	-1.96	-1.90	-1.74	-1.14
Filing Date Shares Outstanding	912.96	981.31	883.24	883.24	883.24	883.24
Total Common Shares Outstanding	912.96	981.31	883.24	883.24	883.24	883.24
Working Capital	-878.61	-1,258	-961.51	-739.8	-335.63	411.26
Book Value Per Share	0.81	0.63	0.66	0.86	1.44	1.79
Tangible Book Value	404.73	351.1	285.21	536.31	1,006	1,321
Tangible Book Value Per Share	0.44	0.36	0.32	0.61	1.14	1.50
Buildings	-	-	1,577	1,560	1,537	1,058
Machinery	-	-	896.3	832.92	774.95	769.85
Construction In Progress	-	-	37.11	67.32	153.99	699.74

Source: S&P Global Market Intelligence. Standard template. Financial Sources.